Rugo, H. S., Tolaney, S. M., Chan, N., Hamilton, E. P., Sharifi, M. N., Rinn, K., Mchayleh, W., Yerushalmi, R., Vidula, N., O'Shaughnessy, J., Curigliano, G., Cortés, J., Romero, P. M., Lepley, D. M., Theall, K. P., Wasserman, T., Kaklamani, V. G. (2025). Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1070